FSC and RM

STEM CELLS AND REGENARATIVE
MEDICINE
FETAL PROGENITOR CELLS
EmProCell Clinical Research
Pvt. Ltd., Mumbai
SPEAKER:
PROFESSOR
KUKHARCHUK OLEKSANDR
Currently in EmProCell cryobank we have fetal stem cells of the brain, spinal cord, heart,
lungs, liver, kidneys, pancreas and adrenal, muscles and bones, skin and placenta. We are
open for collaboration in the field of Regenerative Medicine.
Contact us: prof@emprocell.com, priya@emprocell.com

TRANSPLNATATION OF STEM CELLS WITHOUT ITS
PRELIMINARY DIFFERENTIATION INTO
SPECIALIZED TISSUE – IS PLAYING WITH RUSSIAN
ROULETTE

FETAL PROGENITOR CELLS ARE THE CELLS
DERIVED FROM THE TISSUES OF ABORTUS FETUS
• The following types of
cells can be derived from
abortive material of
different gestation terms
(from 6 to 20 weeks):
• - liver progenitor cells
• - neural progenitor cells
• - gastric and intestinal
progenitor cells
• - lung progenitor cells
• - kidney progenitor cells
• - skin progenitor cells
• - bone tissue progenitor
cells
• - pancreatic progenitor
cells

Fetal chondrocytes has high
potential to multiplication,
they can be isolated in
sufficient quantity for
transplantation or for
obtaining specialized fetal
growth factors
Fetal chondrocytes

FETAL PROGENITOR CELLS FROM HEART TISSUE
From fetal heart tissue have
been isolated human fetal
cardiomyocytes, cardiac
human fibroblasts,
adventitial fibroblasts,
human microvascular
endothelial
cells, endothelial progenitor
cells, mesenchymal stem
cells, and vascular smooth
muscle cells.
Transplantation of these
cells is effective for
treatment of myocardial
infarct and dilatation
cardiomyopathy.

HAEMOPOIETIC PROGENITOR CELLS OF FETAL LIVER WITH
PHENOTYPE CD133+
Progenitor hematopoietic
cells of fetal liver capable
to angio-myogeneic
differentiation, stimulates
blood cells formation and
formation of new vessels,
induces central
immunological tolerance
and enables regeneration
of tissues practically all
damaged organs
Ischemic muscle tissue:
the area of myosymplast
with myoni
Three months after cells
transplantation

HEMATOPOIETIC PROGENITOR CELLS OF FETAL LIVER
WITH PHENOTYPE CD133+
Human CD133 fetal liver
progenitor cells promote the
healing of diabetic ischemic
ulcers by paracrine
stimulation of angiogenesis.
Accelerated wound closure
in the presence of
CD133 cells (A, middle) is
associated with higher
temporary wound
capillarization at day 7 (B).
Capillary density declines to
levels of wounds treated with
CD133 cells or collagen gel
alone by day 14 (C)

Tissue of fetal kidney consists all
cellular elements in
developmental stages, which has
potential to replace damaged
(injured) renal structures in
adults.
From 12-13 and till 18-20 weeks of
human gestation:
(a–b) localization of SIX2 to the
MM, predominantly to the CM.
(c–d) shaped bodies and renal
stroma.
(e–f) nephrogenic zone and newly
forming tubules.
(g–h) nephrogenic cortex, parietal
epithelium of fetal glomeruli.
(i–j) some differentiated tubules.
FETAL KIDNEY
PROGENITOR CELLS

Neural fetal progenitor
cells consists from
precursors of primary
neuroglia, dopaminergic
neurons and
oligodendrocytes, that
lies on the grounds of
therapeutical effects of
the fetal neural cells
transplantation in
neurodegenerative
diseases
FETAL NEURAL
PROGENITOR CELLS

FETAL PANCREATIC PROGENITOR CELLS
Fetal pancreas consist
cells – precursors of
Langerhans islets cells,
that could be the basis for
treatment in diabetes
mellitus 1 type

FETAL PROGENITOR CELLS IN BURNS III-A STAGE
TREATMENT
Currently in EmProCell cryobank we have fetal stem cells of the brain, spinal cord, heart, lungs, liver,
kidneys, pancreas and adrenal, muscles and bones, skin and placenta. We are open for collaboration
in the field of Regenerative Medicine. Contact us: prof@emprocell.com, priya@emprocell.com

TRANSPLANTATION OF FETAL PROGENITOR CELLS IN
POSTOPERATIVE PERIOD TO PANCREONECROSIS PATIENTS
Sewing of umbilical cord Ready implant
Insertion of implant on the zone of pancreatic necrosis
De-freezing umbilical cord

POSTOPERATIVE PERIOD TO PANCREONECROSIS
PATIENTS
Removal of cord tissue implant following 3 days after operation

POSTOPERATIVE PERIOD TO PANCREONECROSIS
PATIENTS
Fetal progenitor cells
Introduction of fetal progenitor
cells stem cells in the subclavian
vein
Currently in EmProCell cryobank we have fetal stem cells of the brain, spinal cord, heart, lungs,
liver, kidneys, pancreas and adrenal, muscles and bones, skin and placenta. We are open for
collaboration in the field of Regenerative Medicine. Contact us:
prof@emprocell.com, priya@emprocell.com
Mortality rate reduced to 9 times.
In course of 3 years after treatment
formation of cysts in pancreas were
not observed

CHRONIC LEGS ISCHEMIA
In clinic 65 patients
were examined with
chronic legs ischemia.
Age of patients: from
55 to 78 years.
Patients had last stage
of disease (alternative
treatment – leg
amputation)

CHRONIC LEGS ISCHEMIA
 Surgical treatment: local
injection of Fetal
progenitor cells along the
sclerotic arteries

CHRONIC LEGS ISCHEMIA: CASE REPORT
BEFORE CELL
TRANSPLANTATION
AFTER CELL
TRANSPLANTATION

PATIENTS ESTIMATION ON EFFICACY OF
FETAL PROGENITOR CELLS
TRANSPLANTATION AT THE END OF
IVESTIGATION:
“SIGNIFICANT IMPROVEMENT” – 90%
“IMPROVEMENT” – 10%
“NON SIGNIFICANT IMPROVEMENT” – 0%
“WITHOUT CHANGE” – 0%

 Development program of progenitor cells is determined
in formation of tissue cells of particular type – cardio,
muscle, renal, lung and etc. This means that after
isolation of such cells and introducing to patient
progenitor cells will continue to differentiate
exclusively in the predetermined cells of fetal liver –
fetal hepatoblasts. These cells capable to produce only
hepatocytes in future differentiation – liver cells,
which and will restore damaged cirrhotic liver tissue of
the patient.
 Thus, in time of fetal organs formation, fetal cells lose
stemness, and became progenitor cells.

So first advantage of fetal progenitor cells – they
do not require additional manipulation, related
with expansion and directed differentiation as
such they can be easily isolated in large amount
and they are already restricted under formation
of particular type of tissue. Fetal progenitor
cells after separation ready for use without any
additional manipulation and treatment with
fetal progenitor cells – this is organ-specific
treatmentю
As such fetal progenitor cells are preformed under
formation of specialized tissue cells i.e. THEY
ARE NOT STEM, they NEVER DEVELOP INTO
CANCER CELLS.

Secondly and most significant advantage is fetal
progenitor cells – they are biologically cannot be
source of cancer cells as such they are not stem
cells.
Unique property of fetal progenitor cells – their
capability to penetrate through histo-hematic barrier
inclusive through hemato-plancental barrier – in blood
of mother.
 They circulate in first trimester fetal blood and have
been found to traffic into the maternal circulation,
engrafting in bone marrow, where they remain
microchimeric for decades after pregnancy. Using fetal
progenitor cells in regenerative medicine offers the
practical advantages of avoidance of immune rejection,
increased engraftment, and treatment before disease
pathology sets in.

Fact is in pregnant women blood presence of progenitor
cells of her fetus known earlier and captured special
attention. In nature nothing is coincidence and
unuseful, all has its biological sense. In what is the
biological sense appearance of child’s fetal progenitor
cells in mother’s blood? Fact is that fetus according to
its genetic is transplantat for mother – kind of foreign
organ.
Fetal tissue by protein (antigens) content incompatible
with immune system of the mother due to half of the
protein gene codes received from father. Besides, there
is peculiar kind of move towards perfection – cross
exchange of genes between chromosomes of father and
mother (crossing-over). If such exchange did not
happen than born child would have exactly be half
copy of parents – 50% of mother, and 50% of father.

As the result of crossing-over completely new protein-
antigen characteristics of body arises. Therefore organ
of children do not get engrafted to parents after
transplantation.
So, fetus – foreign “organ” for mother. Subsequently,
during pregnancy period rejection reaction of
transplantant (graft) should start. But immune system
of pregnant women does not react with the protein
antigen of the child. Scientists have searched for the
answer to this question in the peculiarities of the
blood-placental barrier, which, according to some of
them, do not allow the mother's antibodies in the blood
of child. And how then to be with all known Rhesus
conflict when antibodies Rh-negative mother lead to
miscarriage with Rh-positive fetus?

Attempts to explain absence of rejection reaction of the
fetus is that mothers T lymphocytes do not fall in
blood of child or special cells in the placenta inactivate
T cells aggressive to the embryo tissues that too
seemed to be failed. Mothers T-lymphocytes are
observed in the fetus and they are active. Moreover
during pregnancy mothers immune system
components protects fetus from infectious agents.
So why do fetus not rejected by the immune system of
the mother? As the result of long-term scientific work
of EmProCell staff was shown that these fetal
progenitor cells joins the pregnant women’s blood
inducing immune tolerance – condition in which child
body accepted by mother’s body as its own “organ”.

This continues for 9 months, followed by a sudden
change in mother’s hormonal levels that blocks
immune tolerance to the fetus and birth occurs. Note
that childbirth - a typical acute graft rejection when
transplanted organ such as the kidney, is rejected
together with surgical sutures junction from donor
kidney vessels and vessels of the recipient. The joining
place of child’s body and the mother – placenta.
Particularly from the moment of placental abruption
physiological childbirth begins.

Consequently, fetal progenitor cells have one
more highly significant properties – they are
capable of inducing immune tolerance to
themselves! This means that after introduction
of fetal stem cells to patient they do not reject by
the patient’s immune system, they easily get
engrafted and fulfils its function – replaces
damaged disease tissue of the patient’s body.

 THE NEW ENGLAND JOURNAL OF MEDICINE
(1995), 332 (17), 1118-1124.
NEUROPATHOLOGICAL EVIDENCE OF GRAFT
SURVIVAL AND STRIATAL REINNERVATION
AFTER THE TRANSPLANTATION OF FETAL
MESENCEPHALIC TISSUE IN A PATIENT WITH
PARKINSON’S DISEASE
JEFFREY H. KORDOWER , THOMAS B. FREEMAN,
BARRY J. SNOW, FRANÇOIS J.G. VINGERHOETS ,
ELLIOTT J. MUFSON, PAUL R. SANBERG,
ROBERT A. HAUSER, DONALD A. SMITH, G.
MICHAEL NAUERT, DANIEL P. PERL, C. WARREN
OLANOW

Mov Disord. 1998 May;13(3):383-93.
Fetal nigral grafts survive and mediate clinical
benefit in a patient with Parkinson's disease
Kordower JH, Freeman TB, Chen EY, Mufson EJ,
Sanberg PR, Hauser RA, Snow B, Olanow CW.

Fetal Progenitor Cells & Spinal Injury
 USEFULNESS. By EmProCell organ-specific treatment
technology – not less 70 units.
 RISK. Progenitor cells are ready for use; no cancer
transformation; no reaction of transplant rejection – 1 unit.
 PRICE. From 5000 till 5000 USD – 1 unit.
 USEFULNESS / RISK / PRICE: 70 / 1 / 1 = 70 units.
 Remember, that maximum level of USEFULNESS /
RISK / PRICE = 100 units.

Fetal Progenitor Cells & Non-organ-specific & organ-specific
autoimmune diseases
 Remember, that maximum level of USEFULNESS / RISK /
PRICE = 100 units.

Fetal Progenitor Cells & Liver Cirrhosis
PRICE = 100 units.

Fetal Progenitor Cells & chronic leg ischemia and non-
healing wounds / ulcers
PRICE = 100 units.

FSC and RM

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

En vedette

En vedette (11)

Similaire à FSC and RM

Similaire à FSC and RM (20)

Plus de EmProcell Clinical Research Private Limited, Mumbai, INDIA.

Plus de EmProcell Clinical Research Private Limited, Mumbai, INDIA. (9)

FSC and RM